Paul Tudor Jones Halozyme Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$39.51 - $51.45 $821,215 - $1.07 Million	-20,785 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$25.81 - $43.62 $1.77 Million - $2.98 Million	-68,415 Reduced 76.7%	20,785 $888,000
Q3 2020 Nov 16, 2020	BUY	$25.74 - $29.63 $2.3 Million - $2.64 Million	89,200 New	89,200 $2.34 Million
Q2 2018 Aug 14, 2018	SELL	$16.87 - $20.3 $293,082 - $352,671	-17,373 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$17.06 - $21.2 $226,283 - $281,196	-13,264 Reduced 43.29%	17,373 $340,000
Q4 2017 Feb 14, 2018	BUY	$16.75 - $20.8 $198,856 - $246,937	11,872 Added 63.27%	30,637 $621,000
Q3 2017 Nov 14, 2017	BUY	$11.76 - $17.4 $220,676 - $326,511	18,765	18,765 $326,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.